Emergent BioSolutions (EBS) Inventory Average (2011 - 2026)

Emergent BioSolutions' Inventory Average history runs 16 years deep, the most recent figure standing at $335.5 million for Q1 2026.

• On a quarterly basis, Inventory Average rose 7.24% year-over-year to $335.5 million in Q1 2026; TTM through Mar 2026 was $335.5 million, a 7.24% increase from a year earlier, with the FY2025 full-year figure at $327.6 million, up 2.26% from the prior year.
• Inventory Average slipped to $335.5 million in Q1 2026 per EBS's latest filing, from $349.8 million in the prior quarter.
• Across five years, Inventory Average topped out at $476.8 million in Q3 2022 and bottomed at $312.8 million in Q1 2025.
• The 5-year median for Inventory Average is $347.4 million (2025), against an average of $357.9 million.
• Across the five-year window, Inventory Average increased 26.99% in 2022 and fell 25.72% in 2023, its largest moves.
• Year by year, Inventory Average stood at $439.4 million in 2022, then retreated by 22.29% to $341.5 million in 2023, then declined by 7.12% to $317.2 million in 2024, then gained by 10.29% to $349.8 million in 2025, then dropped by 4.1% to $335.5 million in 2026.
• Per Business Quant, the three latest EBS Inventory Average figures stand at $335.5 million (Q1 2026), $349.8 million (Q4 2025), and $347.4 million (Q3 2025).